HER2 Antibodies Market was valued $ 8.93 Bn in 2022 and is expected to reach $ 12.57 Bn by 2029, at a CAGR of 5.0%.Market Introduction and Overview
Human epidermal growth factor receptor 2 (HER2) plays a central role as a prognostic and predictive marker in breast cancer specimens. It is a trans-membrane tyrosine kinase receptor belonging to the family of epidermal growth factor receptors (EGFRs).To know about the Research Methodology :- Request Free Sample Report Among all the chronic diseases worldwide cancer is considered to be the most prevalent disease. Approximately 1,685,210 new cancer cases were diagnosed and about 595,690 cancer deaths in the US in year 2016. Whereas around 2,600 men and 246,660 that is about 29% women were diagnosed with breast cancer in year 2016. HER2 breast cancer is one of the aggressive type of breast cancer, caused due to over-expression of the HER2 protein. Breast cancers that overexpress the HER2 protein (known as HER2+) make up about 20% of the cases. HER2 positive breast cancer inclines to grow more rapidly than HER2 negative breast cancer. The factors such as being overweight, long term heavy smoking, use of menopausal hormone therapy, alcohol consumption, physical inactivity and many more are responsible for increasing risk of breast cancer. Increasing incidence of breast cancer is expected to lead to increase in demand for targeted therapies and boost the growth of the HER2 antibodies market during the forecast period. Emphasis on standardization of procedures, internal and external quality control assessment affect the market growth positively. Competency evaluation of already existing methods to ensure accurate, reliable, and clinically meaningful test results is helping the market grow upwards. Development of new robust and accurate diagnostic assays by key market players is being encouraged, thereby fuelling the growth. In addition, large clinical trials are warranted to identify the technique that most reliably predicts a positive response to anti-HER2 drugs. The report contains detailed analysis of Strengths, Weakness and opportunities of the key players operating in the HER2 Antibodies Market. It also provides information on current market trends, competitive ranking analysis, regional bifurcation, turnover forecasts, industry drivers and the key challenges. The report has profiled more than fifteen key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analysing the market and estimation the size of the same. The growing healthcare infrastructure in each region is different and focus is given on availability of advanced technology and new techniques.
HER2 Antibodies Market Segment Analysis
By Treatment drugs type, Trastuzumab is estimated to account for 62.1% of the HER2 antibodies market share of the total revenue. The monoclonal antibody trastuzumab is the first HER2-targeting drug approved by the FDA, for cancer treatment. By significantly extending the time to disease progression and overall survival of patients, it has become established in all treatment lines of early and metastatic HER2-positive breast cancer. Trastuzumab is a monoclonal antibody, which is one of the best option to treat breast cancer. It is especially used for breast cancer that is human epidermal growth factor receptor 2 (HER2) positive. Pipeline drugs offer hope for cancer patients, and hence, the healthcare industry has been relying on these drugs to improve the field of oncology. More drugs are in the clinical trials phases and are expected to be approved soon. Increasing cancer prevalence is increasing the demand for new cancer therapeutics from pharmaceuticals, thereby escalating the demand for HER2 antibodies market. By end-use, the hospital segment is expected to register a CAGR of xx% during the forecast period holding an expected revenue value of $xx Mn in the HER2 antibodies Market. Surgeries and other operations are performed majorly in hospitals, due to availability of all tools and technologies required. Testing procedures conducted in hospitals or hospital-attached outpatient facilities enable ease of handling any emergency situations that may arise. Rapid expansion of hospitals coupled with availability of analysers and consumables based on hospital needs is also expanding the segment.HER2 Antibodies Market
Regional Insights North America accounted for the largest share of xx% in 2022, reason being the rising prevalence of cancer. Growth in insurance coverage in the U.S. has increased the burden on the country’s healthcare system, which has highlighted the need for improving efficiency and management of work in North America. Well-established healthcare infrastructure, ease of availability is also a key driver affecting the market growth. Investments by key players in this field has boosted the market growth. Rising adoption of technologically advanced diagnostic imaging systems for lymphedema is rapidly growing the market. Asia Pacific is also expected to witness significant growth during the forecast period due to the increasing geriatric population and rising health care expenditures. The allocation of a large amount of healthcare expenditure for hospitals and dispensing medicines to the elderly is expected drive the market demand. The report also helps in understanding Global HER2 Antibodies Market dynamics, structure by analysing the market segments and project the Global HER2 Antibodies Marketsize. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global HER2 Antibodies Market make the report investor’s guide.HER2 Antibodies Market Scope: Inquire before Buying
Global HER2 Antibodies Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2018 to 2022 Market Size in 2022: US $ 8.93 Bn. Forecast Period 2023 to 2029 CAGR: 5% Market Size in 2029: US $ 12.57 Bn. Segments Covered: by Treatment Drugs type Trastuzumab Lapatinib Ado-trastuzumab emtansine Pertuzumab Everolimus by End User Hospitals pharmacies Retail Pharmacies Others HER2 Antibodies Market, by Region
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)HER2 Antibodies Market, Key Players are
1. Pfizer INC 2. Genentech INC 3. Novartis AG 4. Bio-Techne by Novus Biologicals 5. Abnova Corporation 6. B. Braun Melsungen AG 7. Bovie Medical Corporation 8. Conmed 9. Ethicon Endo-surgery 10. Karl Storz 11. KLS Martin 12. Maxer Endoscopy 13. Medical technologies 14. Medtronic 15. Olympus Corporation 16. Abnova 17. Invivo Gen 18. Biocon 19. Celltrion Frequently Asked Questions: 1. Which region has the largest share in Global HER2 Antibodies Market? Ans: Asia Pacific region held the highest share in 2021. 2. What is the growth rate of Global HER2 Antibodies Market? Ans: The Global HER2 Antibodies Market is growing at a CAGR of 5% during forecasting period 2022-2029. 3. What is scope of the Global HER2 Antibodies Market report? Ans: Global HER2 Antibodies Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global HER2 Antibodies Market? Ans: The important key players in the Global HER2 Antibodies Market are – Pfizer INC, Genentech INC, Novartis AG, Bio-Techne by Novus Biologicals, Abnova Corporation, B. Braun Melsungen AG, Bovie Medical Corporation, Conmed, Ethicon Endo-surgery, Karl Storz, KLS Martin, Maxer Endoscopy, Medical technologies, Medtronic, Olympus Corporation, Abnova, Invivo Gen, Biocon, and Celltrion 5. What is the study period of this Market? Ans: The Global HER2 Antibodies Market is studied from 2021 to 2029.
Global HER2 Antibodies Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: HER2 ANTIBODIES Market Size, By Market Value (US$ Mn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global HER2 ANTIBODIES Market Analysis and Forecast 6.1. HER2 ANTIBODIES Market Size & Yo-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global HER2 ANTIBODIES Market Analysis and Forecast, By Treatment Drugs type 7.1. Introduction and Definition 7.2. Key Findings 7.3. HER2 ANTIBODIES Market Value Share Analysis, By Treatment Drugs type 7.4. HER2 ANTIBODIES Market Size (US$ Mn) Forecast, By Treatment Drugs type 7.5. HER2 ANTIBODIES Market Analysis, By Treatment Drugs type 7.6. HER2 ANTIBODIES Market Attractiveness Analysis, By Treatment Drugs type 8. Global HER2 ANTIBODIES Market Analysis and Forecast, By End users 8.1. Introduction and Definition 8.2. Key Findings 8.3. HER2 ANTIBODIES Market Value Share Analysis, By End users 8.4. HER2 ANTIBODIES Market Size (US$ Mn) Forecast, By End users 8.5. HER2 ANTIBODIES Market Analysis, By End users 8.6. HER2 ANTIBODIES Market Attractiveness Analysis, By End users 9. Global HER2 ANTIBODIES Market Analysis, By Region 9.1. HER2 ANTIBODIES Market Value Share Analysis, By Region 9.2. HER2 ANTIBODIES Market Size (US$ Mn) Forecast, By Region 9.3. HER2 ANTIBODIES Market Attractiveness Analysis, By Region 10. North America HER2 ANTIBODIES Market Analysis 10.1. Key Findings 10.2. North America HER2 ANTIBODIES Market Overview 10.3. North America HER2 ANTIBODIES Market Value Share Analysis, By Treatment Drugs type 10.4. North America HER2 ANTIBODIES Market Forecast, By Treatment Drugs type 10.4.1. Trastuzumab 10.4.2. Lapatinib 10.4.3. Ado-trastuzumab emtansine 10.4.4. Pertuzumab 10.4.5. Everolimus 10.5. North America HER2 ANTIBODIES Market Value Share Analysis, By End users 10.6. North America HER2 ANTIBODIES Market Forecast, By End users 10.6.1. Hospitals pharmacies 10.6.2. Retail Pharmacies 10.6.3. Others 10.7. North America HER2 ANTIBODIES Market Value Share Analysis, By Country 10.8. North America HER2 ANTIBODIES Market Forecast, By Country 10.8.1. U.S. 10.8.2. Canada 10.8.3. Mexico 10.9. North America HER2 ANTIBODIES Market Analysis, By Country 10.10. U.S. HER2 ANTIBODIES Market Forecast, By Treatment Drugs type 10.10.1. Trastuzumab 10.10.2. Lapatinib 10.10.3. Ado-trastuzumab emtansine 10.10.4. Pertuzumab 10.10.5. Everolimus 10.11. U.S. HER2 ANTIBODIES Market Forecast, By End users 10.11.1. Hospitals pharmacies 10.11.2. Retail Pharmacies 10.11.3. Others 10.12. Canada HER2 ANTIBODIES Market Forecast, By Treatment Drugs type 10.12.1. Trastuzumab 10.12.2. Lapatinib 10.12.3. Ado-trastuzumab emtansine 10.12.4. Pertuzumab 10.12.5. Everolimus 10.13. Canada HER2 ANTIBODIES Market Forecast, By End users 10.13.1. Hospitals pharmacies 10.13.2. Retail Pharmacies 10.13.3. Others 10.14. Mexico HER2 ANTIBODIES Market Forecast, By Treatment Drugs type 10.14.1. Trastuzumab 10.14.2. Lapatinib 10.14.3. Ado-trastuzumab emtansine 10.14.4. Pertuzumab 10.14.5. Everolimus 10.15. Mexico HER2 ANTIBODIES Market Forecast, By End users 10.15.1. Hospitals pharmacies 10.15.2. Retail Pharmacies 10.15.3. Others 10.16. North America HER2 ANTIBODIES Market Attractiveness Analysis 10.16.1. By Treatment Drugs type 10.16.2. By End users 10.17. PEST Analysis 10.18. Key Trends 10.19. Key Developments 11. Europe HER2 ANTIBODIES Market Analysis 11.1. Key Findings 11.2. Europe HER2 ANTIBODIES Market Overview 11.3. Europe HER2 ANTIBODIES Market Value Share Analysis, By Treatment Drugs type 11.4. Europe HER2 ANTIBODIES Market Forecast, By Treatment Drugs type 11.4.1. Trastuzumab 11.4.2. Lapatinib 11.4.3. Ado-trastuzumab emtansine 11.4.4. Pertuzumab 11.4.5. Everolimus 11.5. Europe HER2 ANTIBODIES Market Value Share Analysis, By End users 11.6. Europe HER2 ANTIBODIES Market Forecast, By End users 11.6.1. Hospitals pharmacies 11.6.2. Retail Pharmacies 11.6.3. Others 11.7. Europe HER2 ANTIBODIES Market Value Share Analysis, By Country 11.8. Europe HER2 ANTIBODIES Market Forecast, By Country 11.8.1. Germany 11.8.2. U.K. 11.8.3. France 11.8.4. Italy 11.8.5. Spain 11.8.6. Sweden 11.8.7. CIS countries 11.8.8. Rest of Europe 11.9. Germany HER2 ANTIBODIES Market Forecast, By Treatment Drugs type 11.9.1. Trastuzumab 11.9.2. Lapatinib 11.9.3. Ado-trastuzumab emtansine 11.9.4. Pertuzumab 11.9.5. Everolimus 11.10. Germany HER2 ANTIBODIES Market Forecast, By End users 11.10.1. Hospitals pharmacies 11.10.2. Retail Pharmacies 11.10.3. Others 11.11. U.K. HER2 ANTIBODIES Market Forecast, By Treatment Drugs type 11.11.1. Trastuzumab 11.11.2. Lapatinib 11.11.3. Ado-trastuzumab emtansine 11.11.4. Pertuzumab 11.11.5. Everolimus 11.12. U.K. HER2 ANTIBODIES Market Forecast, By End users 11.12.1. Hospitals pharmacies 11.12.2. Retail Pharmacies 11.12.3. Others 11.13. France HER2 ANTIBODIES Market Forecast, By Treatment Drugs type 11.13.1. Trastuzumab 11.13.2. Lapatinib 11.13.3. Ado-trastuzumab emtansine 11.13.4. Pertuzumab 11.13.5. Everolimus 11.14. France HER2 ANTIBODIES Market Forecast, By End users 11.14.1. Hospitals pharmacies 11.14.2. Retail Pharmacies 11.14.3. Others 11.15. Italy HER2 ANTIBODIES Market Forecast, By Treatment Drugs type 11.15.1. Trastuzumab 11.15.2. Lapatinib 11.15.3. Ado-trastuzumab emtansine 11.15.4. Pertuzumab 11.15.5. Everolimus 11.16. Italy HER2 ANTIBODIES Market Forecast, By End users 11.16.1. Hospitals pharmacies 11.16.2. Retail Pharmacies 11.16.3. Others 11.17. Spain HER2 ANTIBODIES Market Forecast, By Treatment Drugs type 11.17.1. Trastuzumab 11.17.2. Lapatinib 11.17.3. Ado-trastuzumab emtansine 11.17.4. Pertuzumab 11.17.5. Everolimus 11.18. Spain HER2 ANTIBODIES Market Forecast, By End users 11.18.1. Hospitals pharmacies 11.18.2. Retail Pharmacies 11.18.3. Others 11.19. Sweden HER2 ANTIBODIES Market Forecast, By Treatment Drugs type 11.19.1. Trastuzumab 11.19.2. Lapatinib 11.19.3. Ado-trastuzumab emtansine 11.19.4. Pertuzumab 11.19.5. Everolimus 11.20. Sweden HER2 ANTIBODIES Market Forecast, By End users 11.20.1. Hospitals pharmacies 11.20.2. Retail Pharmacies 11.20.3. Others 11.21. CIS countries HER2 ANTIBODIES Market Forecast, By Treatment Drugs type 11.21.1. Trastuzumab 11.21.2. Lapatinib 11.21.3. Ado-trastuzumab emtansine 11.21.4. Pertuzumab 11.21.5. Everolimus 11.22. CIS countries HER2 ANTIBODIES Market Forecast, By End users 11.22.1. Hospitals pharmacies 11.22.2. Retail Pharmacies 11.22.3. Others 11.23. Rest of Europe HER2 ANTIBODIES Market Forecast, By Treatment Drugs type 11.23.1. Trastuzumab 11.23.2. Lapatinib 11.23.3. Ado-trastuzumab emtansine 11.23.4. Pertuzumab 11.23.5. Everolimus 11.24. Rest of Europe HER2 ANTIBODIES Market Forecast, By End users 11.24.1. Hospitals pharmacies 11.24.2. Retail Pharmacies 11.24.3. Others 11.25. Europe HER2 ANTIBODIES Market Attractiveness Analysis 11.25.1. By End users 11.25.2. By Treatment Drugs type 11.26. PEST Analysis 11.27. Key Trends 11.28. Key Developments 12. Asia Pacific HER2 ANTIBODIES Market Analysis 12.1. Key Findings 12.2. Asia Pacific HER2 ANTIBODIES Market Overview 12.3. Asia Pacific HER2 ANTIBODIES Market Value Share Analysis, By Treatment Drugs type 12.4. Asia Pacific HER2 ANTIBODIES Market Forecast, By Treatment Drugs type 12.4.1. Trastuzumab 12.4.2. Lapatinib 12.4.3. Ado-trastuzumab emtansine 12.4.4. Pertuzumab 12.4.5. Everolimus 12.5. Asia Pacific HER2 ANTIBODIES Market Value Share Analysis, By End users 12.6. Asia Pacific HER2 ANTIBODIES Market Forecast, By End users 12.6.1. Hospitals pharmacies 12.6.2. Retail Pharmacies 12.6.3. Others 12.7. Asia Pacific HER2 ANTIBODIES Market Value Share Analysis, By Country 12.8. Asia Pacific HER2 ANTIBODIES Market Forecast, By Country 12.8.1. China 12.8.2. India 12.8.3. Japan 12.8.4. South Korea 12.8.5. Australia 12.8.6. ASEAN 12.8.7. Rest of Asia Pacific 12.9. Asia Pacific HER2 ANTIBODIES Market Analysis, By Country 12.10. China HER2 ANTIBODIES Market Forecast, By Treatment Drugs type 12.10.1. Trastuzumab 12.10.2. Lapatinib 12.10.3. Ado-trastuzumab emtansine 12.10.4. Pertuzumab 12.10.5. Everolimus 12.11. China HER2 ANTIBODIES Market Forecast, By End users 12.11.1. Hospitals pharmacies 12.11.2. Retail Pharmacies 12.11.3. Others 12.12. India HER2 ANTIBODIES Market Forecast, By Treatment Drugs type 12.12.1. Trastuzumab 12.12.2. Lapatinib 12.12.3. Ado-trastuzumab emtansine 12.12.4. Pertuzumab 12.12.5. Everolimus 12.13. India HER2 ANTIBODIES Market Forecast, By End users 12.13.1. Hospitals pharmacies 12.13.2. Retail Pharmacies 12.13.3. Others 12.14. Japan HER2 ANTIBODIES Market Forecast, By Treatment Drugs type 12.14.1. Trastuzumab 12.14.2. Lapatinib 12.14.3. Ado-trastuzumab emtansine 12.14.4. Pertuzumab 12.14.5. Everolimus 12.15. Japan HER2 ANTIBODIES Market Forecast, By End users 12.15.1. Hospitals pharmacies 12.15.2. Retail Pharmacies 12.15.3. Others 12.16. South Korea HER2 ANTIBODIES Market Forecast, By Treatment Drugs type 12.16.1. Trastuzumab 12.16.2. Lapatinib 12.16.3. Ado-trastuzumab emtansine 12.16.4. Pertuzumab 12.16.5. Everolimus 12.17. South Korea HER2 ANTIBODIES Market Forecast, By End users 12.17.1. Hospitals pharmacies 12.17.2. Retail Pharmacies 12.17.3. Others 12.18. Australia HER2 ANTIBODIES Market Forecast, By Treatment Drugs type 12.18.1. Trastuzumab 12.18.2. Lapatinib 12.18.3. Ado-trastuzumab emtansine 12.18.4. Pertuzumab 12.18.5. Everolimus 12.19. Australia HER2 ANTIBODIES Market Forecast, By End users 12.19.1. Hospitals pharmacies 12.19.2. Retail Pharmacies 12.19.3. Others 12.20. ASEAN HER2 ANTIBODIES Market Forecast, By Treatment Drugs type 12.20.1. Trastuzumab 12.20.2. Lapatinib 12.20.3. Ado-trastuzumab emtansine 12.20.4. Pertuzumab 12.20.5. Everolimus 12.21. ASEAN HER2 ANTIBODIES Market Forecast, By End users 12.21.1. Hospitals pharmacies 12.21.2. Retail Pharmacies 12.21.3. Others 12.22. Rest of Asia Pacific HER2 ANTIBODIES Market Forecast, By Treatment Drugs type 12.22.1. Trastuzumab 12.22.2. Lapatinib 12.22.3. Ado-trastuzumab emtansine 12.22.4. Pertuzumab 12.22.5. Everolimus 12.23. Rest of Asia Pacific HER2 ANTIBODIES Market Forecast, By End users 12.23.1. Hospitals pharmacies 12.23.2. Retail Pharmacies 12.23.3. Others 12.24. Asia Pacific HER2 ANTIBODIES Market Attractiveness Analysis 12.24.1. By Treatment Drugs type 12.24.2. By End users 12.25. PEST Analysis 12.26. Key Trends 12.27. Key Developments 13. Middle East & Africa HER2 ANTIBODIES Market Analysis 13.1. Key Findings 13.2. Middle East & Africa HER2 ANTIBODIES Market Overview 13.3. Middle East & Africa HER2 ANTIBODIES Market Value Share Analysis, By Treatment Drugs type 13.4. Middle East & Africa HER2 ANTIBODIES Market Forecast, By Treatment Drugs type 13.4.1. Trastuzumab 13.4.2. Lapatinib 13.4.3. Ado-trastuzumab emtansine 13.4.4. Pertuzumab 13.4.5. Everolimus 13.5. Middle East & Africa HER2 ANTIBODIES Market Value Share Analysis, By End users 13.6. Middle East & Africa HER2 ANTIBODIES Market Forecast, By End users 13.6.1. Hospitals pharmacies 13.6.2. Retail Pharmacies 13.6.3. Others 13.7. Middle East & Africa HER2 ANTIBODIES Market Value Share Analysis, By Country 13.8. Middle East & Africa HER2 ANTIBODIES Market Forecast, By Country 13.8.1. GCC Countries 13.8.2. South Africa 13.8.3. Nigeria 13.8.4. Egypt 13.8.5. Rest of Middle East & Africa 13.9. Middle East & Africa HER2 ANTIBODIES Market Analysis, By Country 13.10. GCC Countries HER2 ANTIBODIES Market Forecast, By Treatment Drugs type 13.10.1. Trastuzumab 13.10.2. Lapatinib 13.10.3. Ado-trastuzumab emtansine 13.10.4. Pertuzumab 13.10.5. Everolimus 13.11. GCC Countries HER2 ANTIBODIES Market Forecast, By End users 13.11.1. Hospitals pharmacies 13.11.2. Retail Pharmacies 13.11.3. Others 13.12. South Africa HER2 ANTIBODIES Market Forecast, By Treatment Drugs type 13.12.1. Trastuzumab 13.12.2. Lapatinib 13.12.3. Ado-trastuzumab emtansine 13.12.4. Pertuzumab 13.12.5. Everolimus 13.13. South Africa HER2 ANTIBODIES Market Forecast, By End users 13.13.1. Hospitals pharmacies 13.13.2. Retail Pharmacies 13.13.3. Others 13.14. Nigeria HER2 ANTIBODIES Market Forecast, By Treatment Drugs type 13.14.1. Trastuzumab 13.14.2. Lapatinib 13.14.3. Ado-trastuzumab emtansine 13.14.4. Pertuzumab 13.14.5. Everolimus 13.15. Nigeria HER2 ANTIBODIES Market Forecast, By End users 13.15.1. Hospitals pharmacies 13.15.2. Retail Pharmacies 13.15.3. Others 13.16. Egypt HER2 ANTIBODIES Market Forecast, By Treatment Drugs type 13.16.1. Trastuzumab 13.16.2. Lapatinib 13.16.3. Ado-trastuzumab emtansine 13.16.4. Pertuzumab 13.16.5. Everolimus 13.17. Egypt HER2 ANTIBODIES Market Forecast, By End users 13.17.1. Hospitals pharmacies 13.17.2. Retail Pharmacies 13.17.3. Others 13.18. Rest of Middle East & Africa HER2 ANTIBODIES Market Forecast, By Treatment Drugs type 13.18.1. Trastuzumab 13.18.2. Lapatinib 13.18.3. Ado-trastuzumab emtansine 13.18.4. Pertuzumab 13.18.5. Everolimus 13.19. Rest of Middle East & Africa HER2 ANTIBODIES Market Forecast, By End users 13.19.1. Hospitals pharmacies 13.19.2. Retail Pharmacies 13.19.3. Others 13.20. Middle East & Africa HER2 ANTIBODIES Market Attractiveness Analysis 13.20.1. By Treatment Drugs type 13.20.2. By End users 13.21. PEST Analysis 13.22. Key Trends 13.23. Key Developments 14. South America HER2 ANTIBODIES Market Analysis 14.1. Key Findings 14.2. South America HER2 ANTIBODIES Market Overview 14.3. South America HER2 ANTIBODIES Market Value Share Analysis, By Treatment Drugs type 14.4. South America HER2 ANTIBODIES Market Forecast, By Treatment Drugs type 14.4.1. Trastuzumab 14.4.2. Lapatinib 14.4.3. Ado-trastuzumab emtansine 14.4.4. Pertuzumab 14.4.5. Everolimus 14.5. South America HER2 ANTIBODIES Market Value Share Analysis, By End users 14.6. South America HER2 ANTIBODIES Market Forecast, By End users 14.6.1. Hospitals pharmacies 14.6.2. Retail Pharmacies 14.6.3. Others 14.7. South America HER2 ANTIBODIES Market Value Share Analysis, By Country 14.8. South America HER2 ANTIBODIES Market Forecast, By Country 14.8.1. Brazil 14.8.2. Colombia 14.8.3. Argentina 14.8.4. Rest of South America 14.9. South America HER2 ANTIBODIES Market Analysis, By Country 14.10. Brazil HER2 ANTIBODIES Market Forecast, By Treatment Drugs type 14.10.1. Trastuzumab 14.10.2. Lapatinib 14.10.3. Ado-trastuzumab emtansine 14.10.4. Pertuzumab 14.10.5. Everolimus 14.11. Brazil HER2 ANTIBODIES Market Forecast, By End users 14.11.1. Hospitals pharmacies 14.11.2. Retail Pharmacies 14.11.3. Others 14.12. Colombia HER2 ANTIBODIES Market Forecast, By Treatment Drugs type 14.12.1. Trastuzumab 14.12.2. Lapatinib 14.12.3. Ado-trastuzumab emtansine 14.12.4. Pertuzumab 14.12.5. Everolimus 14.13. Colombia HER2 ANTIBODIES Market Forecast, By End users 14.13.1. Hospitals pharmacies 14.13.2. Retail Pharmacies 14.13.3. Others 14.14. Argentina HER2 ANTIBODIES Market Forecast, By Treatment Drugs type 14.14.1. Trastuzumab 14.14.2. Lapatinib 14.14.3. Ado-trastuzumab emtansine 14.14.4. Pertuzumab 14.14.5. Everolimus 14.15. Argentina HER2 ANTIBODIES Market Forecast, By End users 14.15.1. Hospitals pharmacies 14.15.2. Retail Pharmacies 14.15.3. Others 14.16. Rest of South America HER2 ANTIBODIES Market Forecast, By Treatment Drugs type 14.16.1. Trastuzumab 14.16.2. Lapatinib 14.16.3. Ado-trastuzumab emtansine 14.16.4. Pertuzumab 14.16.5. Everolimus 14.17. Rest of South America HER2 ANTIBODIES Market Forecast, By End users 14.17.1. Hospitals pharmacies 14.17.2. Retail Pharmacies 14.17.3. Others 14.18. South America HER2 ANTIBODIES Market Attractiveness Analysis 14.18.1. By Treatment Drugs type 14.18.2. By End users 14.19. PEST Analysis 14.20. Key Trends 14.21. Key Developments 15. Company Profiles 15.1. Market Share Analysis, By Company 15.2. Competition Matrix 15.2.1. Competitive Benchmarking of key players By price, presence, market share, End users, and R&D investment 15.2.2. New Product Launches and Product Enhancements 15.2.3. Market Consolidation 15.2.3.1. M&A By Regions, Investment and End users 15.2.3.2. M&A Key Players, Forward Integration and Backward Integration 15.3. Company Profiles: Key Players 15.3.1. Pfizer INC 15.3.1.1. Company Overview 15.3.1.2. Financial Overview 15.3.1.3. Product Portfolio 15.3.1.4. Business Strategy 15.3.1.5. Recent Developments 15.3.1.6. Development Footprint 15.3.2. Genentech INC 15.3.3. Novartis AG 15.3.4. Bio-Techne by Novus Biologicals 15.3.5. Abnova Corporation 15.3.6. B. Braun Melsungen AG 15.3.7. Bovie Medical Corporation 15.3.8. Conmed 15.3.9. Ethicon Endo-surgery 15.3.10. Karl Storz 15.3.11. KLS Martin 15.3.12. Maxer Endoscopy 15.3.13. Medical technologies 15.3.14. Medtronic 15.3.15. Olympus Corporation 15.3.16. Abnova 15.3.17. Invivo Gen 15.3.18. Biocon 15.3.19. Celltrion 15.3.20. Others